The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient.
Abstract
The decision to treat a patient in the intensive care unit (ICU) with neuromuscular blocking agents (NMBAs) (for reasons other than the placement of an endotracheal tube) is a difficult one that is guided more commonly by individual practitioner preference than by standards based on evidence-based medicine. Commonly cited reasons for the use of NMBAs in the ICU are to facilitate mechanical ventilation or different modes of mechanical ventilation and to manage patients with head trauma or tetanus. Independent of the reasons for using NMBAs, we emphasize that all other modalities to improve the clinical situation must be tried, using NMBAs only as a last resort. In 1995, the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM) published guidelines for the use of NMBAs in the ICU. The present document is the result of an attempt to reevaluate the literature that has appeared since the last guidelines were published and, based on that review, to update the recommendations for the use of NMBAs in the ICU. Appendix A summarizes our recommendations. Using methods previously described to evaluate the literature and grade the evidence (1), the task force reviewed the physiology of the neuromuscular receptor, the pharmacology of the NMBAs currently used in the ICU, the means to monitor the degree of blockade, the complications associated with NMBAs, and the economic factors to consider when choosing a drug. NEUROMUSCULAR JUNCTION IN HEALTH AND DISEASE The neuromuscular junction consists of a motor nerve terminus, the neurotransmitter acetylcholine, and the postsynaptic muscle endplate (Fig. 1). The impulse of an action potential causes the release of acetylcholine from synaptic vesicles (each containing about 10,000 molecules of acetylcholine) diffusing across the 20-nm gap to the postsynaptic endplate. The motor endplate contains specialized ligand-gated, nicotinic acetylcholine receptors (nAChRs), which convert the chemical signal (i.e., binding of two acetylcholine molecules) into electrical signals (i.e., a transient permeability change and depolarization in the postsynaptic membrane of striated muscle).Figure 1: Neuromuscular Junction. Schematic model of the organization and structure of the neuromuscular junction, with focus and enlargement on the postsynaptic membrane. Agrin is the nerve-derived protein that triggers receptor clustering during synapse formation. Receptor aggregation appears to occur in distinct steps, however, initiated with acetylcholine receptors (AChR) localized together by rapsyn. Meanwhile, D-dystroglycan, the extracellular component of dystrophin-associated glycoprotein complex (DGC), is the agrin receptor which transduces final AChR clustering. This process utilizes the structural organization of additional proteins like utrophin, which stabilize the mature, immobile domains by interaction with the underlying cytoskeleton (actin). When completed, this process concentrates AChR density 1000-fold compared to typical muscle membrane. ACh = acetylcholine, MuSK = muscle-specific-receptor kirase, MASC = MuSK-accessory specificity component. (Reprinted with permission, from Wall MH, Prielipp RC. Monitoring the neuromuscular junction. In: Lake C, Blitt CD, Hines RL, eds. Clinical Monitoring: Practical Applications for Anesthesia and Critical Care. Philadelphia: W.B. Saunders, 2000, Figure 10-3.)There are depolarizing and nondepolarizing NMBAs. Depolarizing NMBAs physically resemble acetylcholine and, therefore, bind and activate acetylcholine receptors. Succinylcholine is currently the only available depolarizing NMBA and is not used for long-term use in ICUs. Nondepolarizing NMBAs also bind acetylcholine receptors but do not activate them—they are competitive antagonists. The difference in the mechanism of action also accounts for different effects in certain diseases. If there is a long-term decrease in acetylcholine release, the number of acetylcholine receptors within the muscle increases. This upregulation causes an increased response to depolarizing NMBAs but a resistance to nondepolarizing NMBAs (i.e., more receptors must be blocked). Conditions in which there are fewer acetylcholine receptors (e.g., myasthenia gravis) lead to an increase in sensitivity to nondepolarizing NMBAs. Adult skeletal muscle retains an ability to synthesize both the mature adult nAChR as well as an immature nAChR variant in which a gamma subunit is substituted for the normal epsilon subunit. Synthesis of immature (fetal) receptors may be triggered in the presence of certain diseases (e.g., Guillain-Barré syndrome, stroke) and other conditions producing loss of nerve function. These immature nAChRs are distinguished by three features. First, immature receptors are not localized to the muscle endplate but migrate across the entire membrane surface (2). Second, the immature receptors are metabolically short-lived (<24 hours) and more ionically active, having a 2- to 10-f
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These drugs may improve chest wall compliance, prevent respiratory dyssynchrony, and reduce peak airway pressures [463].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [463]
Citations
Cites
AAEM minimonograph #26: The electrodiagnosis of carpal tunnel syndrome
Stevens, J. C. (1997) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199712)20:12 · Cited by 518
Critical illness myopathy and neuropathy
Latronico, N., Recupero, D., Candiani, A., Guarneri, B., De Maria, G., Antonini, L., Fenzi, F., Tomelleri, G., Tonin, P., & Rizzuto, N. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91074-0 · Cited by 511
Acute myopathy of intensive care: Clinical, electromyographic, and pathological aspects
Lacomis, D., Giuliani, M. J., van Cott, A., & Kramer, D. J. (1996) · Annals of Neurology · doi:10.1002/ana.410400415 · Cited by 281
Muscle weakness in mechanically ventilated patients with severe asthma.
Leatherman, J. W., Fluegel, W. L., David, W. S., Davies, S. F., & Iber, C. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630621 · Cited by 257
Acute necrotizing myopathy of intensive care: Electrophysiological studies
Zochodne, D. W., Ramsay, D. A., Saly, V., Shelley, S., & Moffatt, S. (1994) · Muscle & Nerve · doi:10.1002/mus.880170305 · Cited by 197
Patterns of neurophysiological abnormality in prolonged critical illness
Coakley, J. H., Nagendran, K., Yarwood, G. D., Honavar, M., & Hinds, C. (1998) · Intensive Care Medicine · doi:10.1007/s001340050669 · Cited by 153
Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents
Watling, S., & Dasta, J. F. (1994) · Critical Care Medicine · doi:10.1097/00003246-199405000-00028 · Cited by 148 · cited 1×
“Many drugs, elements, conditions, and diseases affect the duration of activity of NMBAs; diuretics, antiarrhythmic agents, aminoglycosides, magnesium, lithium, hypokalemia, hypothermia, acidosis, and myasthenia gravis all increase the potency of nondepolarizing NMBAs (22).”
BackgroundRudis, M. I., Sikora, C. A., Angus, E., Peterson, E. L., Popovich, J., Hyzy, R. C., & Zarowitz, B. J. (1997) · Critical Care Medicine · doi:10.1097/00003246-199704000-00005 · Cited by 138
Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids
Barohn, R. J., Jackson, C. E., Rogers, S., Ridings, L. W., & McVey, A. (1994) · Muscle & Nerve · doi:10.1002/mus.880170613 · Cited by 131
Critical illness polyneuropathy
Hund, E., Fogel, W., Krieger, D. W., & Hacke, W. (1996) · Critical Care Medicine · doi:10.1097/00003246-199608000-00010 · Cited by 125
Research works printed but not linked: 10
- Prielipp, 1994, New Horizons, 2, 34
- Tobias, 1995, Anesth Analg, 81, 13
- Khuenl-Brady, 1995, Eur J Anaesthesiol Suppl, 11, 79
- Prielipp, 1995, Anesth Analg, 81, 3
- Miller, 1995, Anesth Analg, 81, 1
- Werba, 1997, Acta Anaesthesiol Scan Suppl, 111, 109
- Frankel, 1996, Am Surg, 62, 503
- Road, 1997, Muscle Nerve, 20, 1587, 10.1002/(SICI)1097-4598(199712)20:12<1587::AID-MUS15>3.0.CO;2-Y · doi:10.1002/(sici)1097-4598(199712)20:12<1587::aid-mus15>3.0.co;2-y
- David, 1998, Electromyogr Clin Neurophysiol, 38, 371
- Faragher, 1996, Muscle Nerve, 19, 516, 10.1002/(SICI)1097-4598(199604)19:4<516::AID-MUS11>3.0.CO;2-N · doi:10.1002/(sici)1097-4598(199604)19:4<516::aid-mus11>3.0.co;2-n
Cited by
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Metadata
- Authors
- Murray, M. J., Cowen, J., DeBlock, H., Erstad, B., Gray, A. W., Tescher, A. N., McGee, W. T., Prielipp, R. C., Susla, G., Jacobi, J., Nasraway, S. A., & Lumb, P. D.
- Affiliations
- Society of Critical Care Medicine (US)
- Venue
- Critical Care Medicine
- Published
- 2002-01
- Volume
- 30
- Issue
- 1
- Pages
- 142-156
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W4245525675
- Cited by
- 283
- References
- 66
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 3 · 2022: 6 · 2021: 14 · 2020: 10 · 2019: 9 · 2018: 10 · 2017: 17 · 2016: 13 · 2015: 10 · 2014: 10 · 2013: 23 · 2012: 15
- FWCI
- 16.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Intensive Care Unit Cognitive Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Keywords
- neuromuscular blockade, neuromuscular blocking agents, intensive care unit, critically ill adults, neuromuscular junction, nicotinic acetylcholine receptors, neuromuscular monitoring, mechanical ventilation, head trauma, tetanus, agrin, acetylcholine release, evidence-based recommendations
- MeSH terms
- Adult, Critical Care, Humans, Monitoring, Physiologic, Neuromuscular Blocking Agents, Neuromuscular Junction, Critical Illness, Neuromuscular Blockade
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. https://app.cochat.ai/papers/10.1097/00003246-200201000-00021
- The paper
- Murray, M. J., Cowen, J., DeBlock, H., Erstad, B., Gray, A. W., Tescher, A. N., McGee, W. T., Prielipp, R. C., Susla, G., Jacobi, J., Nasraway, S. A., & Lumb, P. D. (2002). Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Critical Care Medicine. https://doi.org/10.1097/00003246-200201000-00021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.